We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
0
0 active
Approvals
Total approvals
Agencies
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No approval data available
- SK Life Science will present ten posters at the 2026 American Academy of Neurology Annual Meeting showcasing cenobamate's clinical outcomes, real-world evidence, and pharmacokinetic data across multiple patient populations. - The presentations include new analysis from the "Hope, Hesitancy, and Hard Truths" survey examining communication barriers between epilepsy patients and healthcare providers, building on findings first shared during National Epilepsy Awareness Month. - Clinical data will cover cenobamate's efficacy in primary generalized tonic-clonic seizures in adults and adolescents, healthcare utilization outcomes, and long-term safety results from multinational populations. - Research findings address critical unmet needs in epilepsy care, where nearly 40% of the 3.4 million Americans with epilepsy do not achieve seizure freedom despite available treatments.
